Morning Overview on MSN
Multiple myeloma patients can now get the drug Sarclisa as a quick under-the-skin shot
People living with relapsed or refractory multiple myeloma now have a faster way to receive one of their key treatments. The ...
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
The FDA has approved a subcutaneous version of isatuximab (Sarclisa Escena, Sanofi-Aventis) for several multiple myeloma (MM) ...
Hosted on MSN
FDA Approves New Subcutaneous (Under-the-Skin) Option for Keytruda: What It Means for Cancer Patients
The U.S. Food and Drug Administration (FDA) has approved a new way to give pembrolizumab (brand name: Keytruda), one of the most widely used immunotherapy treatments for cancer. For the first time, ...
Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...
A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...
Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed noninferiority ...
Ocrevus Zunovo is the first and only biannual professional-administered ~10 min SC injection approved for both forms of multiple sclerosis. The subcutaneous formulation of Tecentriq received its first ...
Rybrevant Faspro is a new under-the-skin (subcutaneous) injection form of the cancer medicine Rybrevant (amivantamab). The FDA has now approved it in combination with another medicine called ...
FDA approved subcutaneous Opdivo for solid tumors, excluding dual immunotherapy with Yervoy, enhancing treatment convenience and accessibility. CHECKMATE-67T trial showed subcutaneous Opdivo's ...
FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...
Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results